Fig. 7
From: NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus
NIK inhibition improves survival and proteinuria in NZB/W F1 mice. a Experimental design. Lupus prone NZB/W F1 mice were accelerated with adenovirally delivered IFNα and treated with NIK SMI1, BR3-mIgG2a or appropriate controls for 84 days. b, c Kaplan–Meier curves of percent survival when treated with NIK SMI1 (b) or BR3-mIgG2a (c). d, e Proteinuria scores of mice treated with NIK SMI1 (d) or BR3-mIgG2a (e). Proteinuria data are represented as mean ± standard error of the mean of 15 mice for each timepoint. For deceased mice, a proteinuria score of 5 was carried forward. Statistics: survival, Mantel–Cox test; for proteinuria, area under the curve (AUC) from day 19–84 was calculated for each animal, and groups were compared by one-way ANOVA with Sidak’s test for multiple comparisons
